Table 5. Six-month events of all study patients .
| Variable | Uric acid ≤ 5.7 (n = 291) | Uric acid > 5.7 (n = 143) | p value |
| All-cause mortality, n (%) | 12 (4.1) | 28 (19.6) | < 0.001 |
| Cardiovascular mortality, n (%) | 12 (4.1) | 25 (17.5) | < 0.001 |
| Non-cardiac mortality, n (%) | 0 | 3 (2.1) | 0.01 |
| Fatal reinfarction, n (%) | 8 (2.7) | 14 (9.8) | 0.002 |
| Target-vessel revascularization, n (%) | 21 (7.2) | 16 (11.2) | 0.16 |
| Stroke, n (%) | 1 (0.3) | 4 (2.8) | 0.02 |
| Advanced heart failure, n (%) | 46 (15.8) | 47 (32.9) | < 0.001 |
| Cardiac-hospitalization, n (%) | 53 (18.2) | 37 (25.9) | 0.06 |
| MACE, n (%) | 32 (11) | 38 (26.6) | < 0.001 |
MACE, major adverse cardiac events (cardiovascular mortality, reinfarction, target-vessel revascularization).